304 related articles for article (PubMed ID: 15816481)
1. The concentration of Fas in the serum and liver tissue in viral chronic hepatitis B patients treated with lamivudine.
Lapinski TW
Hepatogastroenterology; 2005; 52(62):575-9. PubMed ID: 15816481
[TBL] [Abstract][Full Text] [Related]
2. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Kao JH; Chen DS
Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
[TBL] [Abstract][Full Text] [Related]
4. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing outcome of lamivudine in anti-HBe-positive chronic hepatitis B.
Ascione A; Ascione T; Lanza AG; Utech W; Di Costanzo GG; Macri M
Hepatogastroenterology; 2006; 53(72):919-23. PubMed ID: 17153453
[TBL] [Abstract][Full Text] [Related]
6. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia.
Bozkaya H; Yurdaydin C; Idilman R; Tüzün A; Cinar K; Erkan O; Bozdayi AM; Erden E; Uzun Y; Cetinkaya H; Uzunalimoglu O
Antivir Ther; 2005; 10(2):319-25. PubMed ID: 15865226
[TBL] [Abstract][Full Text] [Related]
7. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
Lai CL; Chien RN; Leung NW; Chang TT; Guan R; Tai DI; Ng KY; Wu PC; Dent JC; Barber J; Stephenson SL; Gray DF
N Engl J Med; 1998 Jul; 339(2):61-8. PubMed ID: 9654535
[TBL] [Abstract][Full Text] [Related]
8. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
[TBL] [Abstract][Full Text] [Related]
9. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients.
Wang CC; Liu CJ; Lai MY; Kao JH; Chen DS
Liver Int; 2007 Mar; 27(2):235-9. PubMed ID: 17311619
[TBL] [Abstract][Full Text] [Related]
11. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
Chan HL; Wang H; Niu J; Chim AM; Sung JJ
Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety in chronic hepatitis B adolescent patients with lamivudine therapy].
Lu WL; Xie DY; Yao JL; Yao GB; Cui ZY; Zhang DF; Wu L
Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):429-31. PubMed ID: 15268810
[TBL] [Abstract][Full Text] [Related]
13. Long-term therapy of chronic hepatitis B with lamivudine.
Lau DT; Khokhar MF; Doo E; Ghany MG; Herion D; Park Y; Kleiner DE; Schmid P; Condreay LD; Gauthier J; Kuhns MC; Liang TJ; Hoofnagle JH
Hepatology; 2000 Oct; 32(4 Pt 1):828-34. PubMed ID: 11003630
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy.
Kim JH; Yu SK; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Lee CH; Byun KS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1220-5. PubMed ID: 17532786
[TBL] [Abstract][Full Text] [Related]
15. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
[TBL] [Abstract][Full Text] [Related]
16. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
[TBL] [Abstract][Full Text] [Related]
17. The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.
Shindo M; Hamada K; Nishioji K; Muramatsu A; Oda Y; Okuno T
J Gastroenterol; 2004; 39(3):260-7. PubMed ID: 15065004
[TBL] [Abstract][Full Text] [Related]
18. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B.
Liaw YF; Tsai SL; Chien RN; Yeh CT; Chu CM
Hepatology; 2000 Sep; 32(3):604-9. PubMed ID: 10960456
[TBL] [Abstract][Full Text] [Related]
19. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B.
Akarca US; Ersoz G; Gunsar F; Karasu Z; Saritas E; Yuce G; Batur Y
Antivir Ther; 2004 Jun; 9(3):325-34. PubMed ID: 15259895
[TBL] [Abstract][Full Text] [Related]
20. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]